Navigation Links
Amicus Therapeutics Provides Positive Data Update from Phase 2 Long-Term Extension Study of Amigal™ for Fabry Disease
Date:2/16/2011

for all subjects continuing in the extension study and the average annual rate of change in eGFR in subjects identified as responders to migalastat HCl, excluding hyperfiltrators, was +1.6 mL/min/1.73m2.  Additionally, reduced 24-hour urine protein continues to be observed in multiple subjects identified as responders to migalastat HCl, with a mean 21% and median 34% reduction from baseline in this group of subjects.

Co-administration with ERT in Fabry Disease and Pompe DiseaseAmicus previously reported promising preclinical data demonstrating that the co-administration of a pharmacological chaperone with ERT has the potential to address key limitations of ERT. The addition of a pharmacological chaperone has been shown to prevent the loss of activity of ERT in the circulation, increase tissue uptake, and increase substrate reduction in multiple disease-relevant tissues. Preclinical proof of concept has been established for Fabry disease and Pompe disease.

The Company will present a review of new and historical data from preclinical studies of migalastat HCl co-administered with ERT in an animal model of Fabry disease.  Amicus and its partner GlaxoSmithKline PLC (GSK) are sponsoring an ongoing Phase 2 study evaluating the co-administration of migalastat HCl with ERT for Fabry disease.  Results from this study are expected in the second half of 2011.

In addition, Amicus will present pharmacokinetics and muscle distribution data from a Phase 1 study of AT2220 that support the planned Phase 2 clinical study of AT2220 co-administered with ERT in Pompe patients.  The Company expects to initiate this study in the first half of 2011 and to report preliminary results in the second half of 2011. The Company intends to seek U.S. FDA approval to lift the current hold on the AT2220 program as part of its development plan.

Diseases of NeurodegenerationAmicus is investigating the potential use of pharmacological chaperones f
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
2. Amicus Therapeutics Opens Research Facility in San Diego
3. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
4. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
5. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
6. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
7. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
8. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
9. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
10. Amicus Therapeutics Announces Change to Board of Directors
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 2014  RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" ... Fourth International Symposium on Thymosins in Health and Disease ... "When thymosin beta 4 (TB4) linked with rhodamine ... cavity in a rodent model of stroke, it was ... parenchyma (the functional tissue of the brain).   The leakage ...
(Date:10/25/2014)... Oct 24, 2014 Research and Markets ... Market by Product , Research Area & by End ... their offering. In this report, the ... products, research areas, and end users. The product segments ... enzymes, instruments & consumables, kits, and reagents. The subsegments ...
(Date:10/22/2014)... , Oct. 22, 2014 New test ... the in vitro diagnostic (IVD) test industry, especially as ... healthcare market researcher listed more than 25 testing innovations ... be the future of IVD products. Kalorama details the new ... The Worldwide Market for In Vitro Diagnostic Tests ...
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis plc ... pharmaceutical company, and Rhythm, a biopharmaceutical company, today announced ... acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., which ... the treatment of diabetic gastroparesis and other GI functional ... Phase 2 trial of relamorelin for the treatment of ...
Breaking Biology Technology:Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5
... 9 A homegrown New Jersey company is,earning ... of pharmaceuticals everywhere. Secure Symbology, (http://www.securesymbology.com ), a ... an,Honored Finalist as Emerging Business of the Year ... its vision to wipe out counterfeit drugs,worldwide. ...
... Extension Provides Members of University HealthSystem Consortium With Broad ... ... 9 Baxter International,Inc. (NYSE: BAX ) announced today ... signed a new two-year,contract extension on behalf of UHC valued ...
... Cell Therapeutics, Inc. (CTI),(Nasdaq: CTIC ; MTAX) management will present at ... pm at,the Palace Hotel in San Francisco. The conference will also ... webcast can be accessed at, http://www.cticseattle.com . ... BIO CEO & Investor Conference ...
Cached Biology Technology:Secure Symbology: Making New Jersey Proud While Saving Lives 2Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products 2Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products 3
(Date:10/17/2014)... have shown for the first time how bacteria can ... giving them the opportunity to get tremendous insights into ... study also discovered the bacterial growth in chronic lung ... slowed down by the immune cells. The researchers discovered ... "suffocate" the bacteria, forcing the bacteria to switch to ...
(Date:10/16/2014)... constantly wages war on the human body. Battles ... stalemate. In pancreatic cancer, this stalemate—known as tumor ... aggressively malignant, a phenomena that is poorly understood. ... the laboratory of Salvatore Torquato, a Professor of ... conditions surrounding tumor dormancy and the switch to ...
(Date:10/16/2014)... synthesis of recent research findings to inform their management ... states. , The Ecology and Management of Moist ... of the Relevant Biophysical Science and Implications for Future ... U.S. Forest Service,s Pacific Northwest Research Station, is a ... synthesis of the large body of scientific information on ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Modeling tumor dormancy 2New report synthesizes best available science on management of moist mixed-conifer forests 2
... of Virginia researchers have discovered that microRNAs, a form of ... , In the May 1 issue of Genes & ... have shown that microRNAs can suppress the overexpression of a ... fatty tissue and certain tumors, as well as diet-induced obesity. ...
... uncovered evidence that baby fish, only millimetres long, manage to ... of open sea by using their sense of smell. , ... Mike Kingsford of the ARC Centre of Excellence for Coral ... Hole, USA, also shines a new light on how the ...
... of York have won a grant of £110,000 to investigate ... Dr Jason Lynam and Dr Ian Fairlamb, of the University's ... Leverhulme Trust for a three-year study into the use of ... the bloodstream. , Carbon monoxide is an anti-inflammatory, and ...
Cached Biology News:Baby fish 'smell their way home' 2Research to spotlight carbon monoxide benefits 2
... a metabolically stable analog of ... uterine stimulant and abortifacient which ... induce labor. It induces luteolysis ... when given as an intramuscular ...
... a member of a class of proteins who ... sequence. Mut S plays an integral role in ... transcription-coupled nucleotide excision repair and in preventing chromosomal ... binds to DNA specifically at base pair mismatches ...
... Glutathione-S-transferases (GSTs) are a group of enzymes ... xenobiotics in mammals. The enzymes protect cells ... of the glutathione to electrophilic xenobiotics, and ... and toxic effects of the compounds. GST ...
... Monoclonal Antibody Epitope: A ... Recommended Storage: Store vial ... contents and freeze at -20 C or below ... and thawing. Centrifuge product if not completely ...
Biology Products: